Fig. 15 | Scientific Reports

Fig. 15

From: Unveiling Isorhapontigenin’s therapeutic potential in lung cancer via integrated network pharmacology, molecular docking, and experimental validation

Fig. 15

CCK-8 assay of PC9 cell viability after 24- and 48-h treatment with Isorhapontigenin (n = 4 biological replicates). Compared to the Control group, Isorhapontigenin exhibited concentration- and time-dependent inhibition of PC9 cell activity. * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, **** indicates P < 0.0001.

Back to article page